GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Financiere de Tubize SA (XBRU:TUB) » Definitions » EV-to-FCF

Financiere de Tubize (XBRU:TUB) EV-to-FCF

: -2,048.67 (As of Today)
View and export this data going back to 1985. Start your Free Trial

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Financiere de Tubize's Enterprise Value is €4,191.59 Mil. Financiere de Tubize's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 was €-2.05 Mil. Therefore, Financiere de Tubize's EV-to-FCF for today is -2,048.67.

The historical rank and industry rank for Financiere de Tubize's EV-to-FCF or its related term are showing as below:

XBRU:TUB' s EV-to-FCF Range Over the Past 10 Years
Min: -2072.61   Med: 0   Max: 0
Current: -2037.8

XBRU:TUB's EV-to-FCF is ranked worse than
100% of 389 companies
in the Biotechnology industry
Industry Median: 4.27 vs XBRU:TUB: -2037.80

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-04-23), Financiere de Tubize's stock price is €92.40. Financiere de Tubize's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was €1.980. Therefore, Financiere de Tubize's PE Ratio for today is 46.67.


Financiere de Tubize EV-to-FCF Historical Data

The historical data trend for Financiere de Tubize's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Financiere de Tubize Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-FCF
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2,539.36 -1,771.38 -3,459.66 -1,515.75 -1,598.33

Financiere de Tubize Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
EV-to-FCF Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -3,459.66 - -1,515.75 - -1,598.33

Competitive Comparison

For the Biotechnology subindustry, Financiere de Tubize's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Financiere de Tubize EV-to-FCF Distribution

For the Biotechnology industry and Healthcare sector, Financiere de Tubize's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where Financiere de Tubize's EV-to-FCF falls into.



Financiere de Tubize EV-to-FCF Calculation

Financiere de Tubize's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=4191.589/-2.046
=-2,048.67

Financiere de Tubize's current Enterprise Value is €4,191.59 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Financiere de Tubize's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 was €-2.05 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Financiere de Tubize  (XBRU:TUB) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Financiere de Tubize's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=92.40/1.980
=46.67

Financiere de Tubize's share price for today is €92.40.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Financiere de Tubize's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was €1.980.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


Financiere de Tubize EV-to-FCF Related Terms

Thank you for viewing the detailed overview of Financiere de Tubize's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Financiere de Tubize (XBRU:TUB) Business Description

Traded in Other Exchanges
Address
Allée de la Recherche, 60, Brussels, BEL, 1070
Financiere de Tubize SA is a holding company that owns a stake in UCB, a biopharmaceutical company. UCB is a global biotechnology company that develops treatments for conditions related to neurology and immunology. UCB generates the vast majority of its revenue in the United States, followed by Europe and other international markets. Most of its sales revenue is derived from its neurology products, followed by its immunology products. The company's strategy focuses on leveraging scientific advances and skills in areas such as genetics, biomarkers, and human biology.

Financiere de Tubize (XBRU:TUB) Headlines

No Headlines